Humacyte.

PositionTRIANGLE BRIEFS: MORRISVILLE - Humacyte Received Finance from California Institute for Regenerative Medicine - Brief article

Humacyte received $9.9 million from the California Institute for Regenerative Medicine, an agency that promotes stemcell therapies. The investment will help fund clinical trials for Humacyl, the company's flagship product for patients with chronic kidney disease. Started...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT